Related Experiment Video
Updated: Aug 2, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
p16 Gene methylation in colorectal tumors: correlation with clinicopathological features and prognostic value
M T Sanz-Casla1, M L Maestro, M Vidaurreta
1Servicio de Análisis Clínicos, Sección Biología Tumoral, Hospital Clínico San Carlos, Madrid, Spain.
Background:
Methylation of the CpG islands in the p16 gene promoter region is an important transcription repression mechanism that has been identified as an alternative mechanism for inactivating specific genes in cancer. Given that, DNA methylation is a common event in colorectal cancer.
Materials And Methods:
The aim of this study was to establish the methylation status of the p16 gene in 104 patients with colorectal carcinoma and evaluate its prognostic value. DNA was bisulfite-modified and analyzed for p16 promoter methylation by methylation-specific PCR.
Results:
Methylation of thep16 gene was determined in 18.3% of our patient population (19/104). The methylated state did not correlate with any clinicopathological factors. During a median follow-up period of 72 months, the overall survival rate for patients with gene methylation was 75% and without gene methylation it was 61% (p = 0.09).
Conclusions:
Although not statistically significant, this difference indicates a clinically valuable tendency.
